Metastases - malecare.org

Denosumab Demonstrates An Increased Time to First Skeletal Event in Men with Metastatic Prostate Cancer vs Zometa

In men with bone metastasis from castration-resistant prostate cancer (CRPC), a monthly subcutaneous injection with denosumab, 120 mg, is superior to Zometa, a multinational group of researchers reported at the American Society of Clinical Oncology annual meeting. The current standard of care is for men with bone metastasis from castration-resistant prostate cancer (CRPC) is to [...]

By Malecare|2017-10-19T10:53:43-04:00August 11th, 2010|Advanced Prostate Cancer, bisphosphonates, Drugs & Treatments, Metastases, Uncategorized, Understanding APC|0 Comments

A Take Away Point from the Last American Urological Association (AUA) Meeting

The prognosis of patients with advanced prostate cancer who have lymph node metastasis depends on the number of positive lymph nodes removed and Gleason score of the primary tumor. Bilateral pelvic lymph node dissection should be performed in intermediate- and high-risk patients to identify those with minimal nodal burden who may benefit the most from [...]

By Malecare|2010-08-06T11:55:52-04:00August 6th, 2010|Advanced Prostate Cancer, General Information, Metastases, Prostate Ponderings, Uncategorized, Understanding APC|0 Comments

Possible Role of a BRCA1 Gene Loss in Metastatic Prostate Cancer Progression

Genetic counseling is common place in the world of breast cancer including the evaluation of the BRCA genes. Prostate and breast cancer increasingly been shown to have a relationship, perhaps all the down to the genetic level. Researchers are now understanding, that like in breast cancer, BRCA1 loss preexisting in small sub-populations of prostate cancer [...]

By Malecare|2017-10-19T10:53:46-04:00July 22nd, 2010|Advanced Prostate Cancer, General Information, genetics, Metastases, Uncategorized, Understanding APC|0 Comments

Denosumab Demonstrates More Efficacy Than Zometa in Prostate Cancer Patients with Bone Metastases

A phase III study released at the ASCO meeting demonstrated that for men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. […]

By Malecare|2017-10-19T10:53:51-04:00June 6th, 2010|Advanced Prostate Cancer, Drugs & Treatments, General Information, Metastases, Uncategorized, Understanding APC|0 Comments

Analyzing Prostate Cancer Using the CTC-Chip – Insights into the Prognosis of Recurrent Prostate Cancer

Using a CTC-chip that measures the level of circulating tumor cells in blood can provide an important insight into the prognosis and potential rates of recurrent disease, according to data from a developing study at Massachusetts General Hospital, which was presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010. [...]

By Malecare|2010-05-03T11:13:39-04:00May 3rd, 2010|Advanced Prostate Cancer, General Information, Metastases, On The Horizon, Prostate Ponderings, Technology, Uncategorized, Understanding APC|2 Comments